These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20726594)

  • 1. A high-throughput O-glycopeptide discovery platform for seromic profiling.
    Blixt O; Cló E; Nudelman AS; Sørensen KK; Clausen T; Wandall HH; Livingston PO; Clausen H; Jensen KJ
    J Proteome Res; 2010 Oct; 9(10):5250-61. PubMed ID: 20726594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Random glycopeptide bead libraries for seromic biomarker discovery.
    Kracun SK; Cló E; Clausen H; Levery SB; Jensen KJ; Blixt O
    J Proteome Res; 2010 Dec; 9(12):6705-14. PubMed ID: 20886906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.
    Blixt O; Bueti D; Burford B; Allen D; Julien S; Hollingsworth M; Gammerman A; Fentiman I; Taylor-Papadimitriou J; Burchell JM
    Breast Cancer Res; 2011 Mar; 13(2):R25. PubMed ID: 21385452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray.
    Pedersen JW; Blixt O; Bennett EP; Tarp MA; Dar I; Mandel U; Poulsen SS; Pedersen AE; Rasmussen S; Jess P; Clausen H; Wandall HH
    Int J Cancer; 2011 Apr; 128(8):1860-71. PubMed ID: 21344374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes.
    Wandall HH; Blixt O; Tarp MA; Pedersen JW; Bennett EP; Mandel U; Ragupathi G; Livingston PO; Hollingsworth MA; Taylor-Papadimitriou J; Burchell J; Clausen H
    Cancer Res; 2010 Feb; 70(4):1306-13. PubMed ID: 20124478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
    Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
    Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplified Detection of Breast Cancer Autoantibodies Using MUC1-Based Tn Antigen Mimics.
    Guillen-Poza PA; Sánchez-Fernández EM; Artigas G; García Fernández JM; Hinou H; Ortiz Mellet C; Nishimura SI; Garcia-Martin F
    J Med Chem; 2020 Aug; 63(15):8524-8533. PubMed ID: 32672464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer.
    Burford B; Gentry-Maharaj A; Graham R; Allen D; Pedersen JW; Nudelman AS; Blixt O; Fourkala EO; Bueti D; Dawnay A; Ford J; Desai R; David L; Trinder P; Acres B; Schwientek T; Gammerman A; Reis CA; Silva L; Osório H; Hallett R; Wandall HH; Mandel U; Hollingsworth MA; Jacobs I; Fentiman I; Clausen H; Taylor-Papadimitriou J; Menon U; Burchell JM
    Br J Cancer; 2013 May; 108(10):2045-55. PubMed ID: 23652307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
    Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
    Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of antibody binding to mucin glycopeptides in lung cancer.
    Qu J; Yu H; Li F; Zhang C; Trad A; Brooks C; Zhang B; Gong T; Guo Z; Li Y; Ragupathi G; Lou Y; Hwu P; Huang W; Zhou D
    Int J Oncol; 2016 Feb; 48(2):587-94. PubMed ID: 26692014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A straightforward protocol for the preparation of high performance microarray displaying synthetic MUC1 glycopeptides.
    Matsushita T; Takada W; Igarashi K; Naruchi K; Miyoshi R; Garcia-Martin F; Amano M; Hinou H; Nishimura S
    Biochim Biophys Acta; 2014 Mar; 1840(3):1105-16. PubMed ID: 24246952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
    Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
    Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
    Li M; Yu F; Yao C; Wang PG; Liu Y; Zhao W
    Org Biomol Chem; 2018 Feb; 16(6):993-999. PubMed ID: 29345713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
    Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides.
    Liu X; Sejbal J; Kotovych G; Koganty RR; Reddish MA; Jackson L; Gandhi SS; Mendonca AJ; Longenecker BM
    Glycoconj J; 1995 Oct; 12(5):607-17. PubMed ID: 8595249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening.
    Pedersen JW; Gentry-Maharaj A; Nøstdal A; Fourkala EO; Dawnay A; Burnell M; Zaikin A; Burchell J; Papadimitriou JT; Clausen H; Jacobs I; Menon U; Wandall HH
    Int J Cancer; 2014 May; 134(9):2180-88. PubMed ID: 24122770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Tumor-Associated Autoantibodies in the Sera of Pancreatic Cancer Patients Using Engineered MUC1 Glycopeptide Nanoparticle Probes.
    Corzana F; Asín A; Eguskiza A; De Tomi E; Martín-Carnicero A; Martínez-Moral MP; Mangini V; Papi F; Bretón C; Oroz P; Lagartera L; Jiménez-Moreno E; Avenoza A; Busto JH; Nativi C; Asensio JL; Hurtado-Guerrero R; Peregrina JM; Malerba G; Martínez A; Fiammengo R
    Angew Chem Int Ed Engl; 2024 Sep; 63(37):e202407131. PubMed ID: 38935849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.
    Glaffig M; Stergiou N; Schmitt E; Kunz H
    ChemMedChem; 2017 May; 12(10):722-727. PubMed ID: 28440596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.
    Ninkovic T; Kinarsky L; Engelmann K; Pisarev V; Sherman S; Finn OJ; Hanisch FG
    Mol Immunol; 2009 Nov; 47(1):131-40. PubMed ID: 19007994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.